Table 1.
Comparison of clinicopathologic factors based on the intensity of intratumoral hENT1 expression
| Variables | Overall | hENT1 intensity | p-value | |
|---|---|---|---|---|
| 0 to 3 (n=63) | 4 (n=97) | |||
| Age (mean (SD), years) | 64.61 (9.8) | 66.30 (9.1) | 63.50 (10.1) | 0.077 |
| Sex | ||||
| Male | 93 (58.1) | 42 (66.7) | 51 (52.1) | 0.126 |
| Female | 67 (41.9) | 21 (33.3) | 46 (47.9) | |
| Body Mass Index (mean, kg/m2) | 21.76 (3.33) | 21.70 (3.00) | 21.80 (3.55) | 0.848 |
| Diabetes, preoperative | ||||
| Yes | 58 (36.7) | 30 (47.6) | 28 (29.5) | 0.021 |
| No | 100 (63.3) | 33 (52.4) | 67 (70.5) | |
| Preoperative CA19-9 (U/ml) | ||||
| <37 | 46 (29.5) | 15 (24.6) | 31 (32.6) | 0.322 |
| ≥37, <300 | 56 (35.9) | 22 (36.1) | 34 (35.8) | |
| ≥300, <600 | 18 (11.5) | 5 (8.2) | 13 (13.7) | |
| ≥600, <900 | 7 (4.5) | 4 (6.6) | 3 (3.2) | |
| ≥900 | 29 (18.6) | 15 (24.6) | 14 (14.7) | |
| Postoperative CA19-9 (U/ml) | ||||
| <37 | 82 (54.7) | 31 (50.0) | 51 (58.0) | 0.732 |
| ≥37, <300 | 49 (32.7) | 21 (33.9) | 28 (31.8) | |
| ≥300, <600 | 9 (6.0) | 5 (8.1) | 4 (4.5) | |
| ≥600, <900 | 3 (2.0) | 1 (1.6) | 2 (2.3) | |
| ≥900 | 7 (4.7) | 4 (6.5) | 3 (3.4) | |
| Location of tumor | ||||
| Head | 98 (62.0) | 40 (62.5) | 58 (60.4) | 0.502 |
| Body | 20 (12.7) | 6 (9.4) | 14 (14.6) | |
| Body and tail | 8 (5.1) | 2 (3.1) | 6 (6.3) | |
| Tail | 30 (19.0) | 14 (21.9) | 16 (16.7) | |
| Whole pancreas | 4 (2.5) | 2 (3.1) | 2 (2.1) | |
| Type of operation | ||||
| Pancreaticoduodenectomy including pylorus-preserving | 96 (60.0) | 37 (58.7) | 59 (60.8) | 0.818 |
| Distal pancreatectomy | 54 (33.8) | 21 (33.3) | 33 (34.0) | |
| Total pancreatectomy | 6 (3.8) | 2 (3.2) | 4 (4.1) | |
| Others | 4 (2.5) | 3 (4.8) | 1 (1.0) | |
| R0 resection | ||||
| Yes | 137 (85.6) | 54 (84.4) | 83 (86.5) | 0.780 |
| No | 23 (14.4) | 10 (15.6) | 13 (13.5) | |
| T stage | ||||
| T1 | 1 (0.6) | 0 (0.0) | 1 (1.0) | 0.593 |
| T2 | 3 (1.9) | 2 (3.2) | 1 (1.0) | |
| T3 | 150 (93.8) | 58 (92.1) | 92 (94.8) | |
| T4 | 6 (3.8) | 3 (4.8) | 3 (3.1) | |
| N stage | ||||
| N0 | 62 (38.8) | 20 (31.7) | 42 (43.3) | 0.227 |
| N1 | 97 (60.6) | 43 (68.3) | 54 (55.7) | |
| Nx | 1 (0.6) | 0 (0.0) | 1 (1.0) | |
| M stage | ||||
| M0 | 155 (96.9) | 63 (100.0) | 92 (94.8) | 0.172 |
| M1 | 5 (3.1) | 0 (0.0) | 5 (5.2) | |
| Stage, AJCC 8th | ||||
| IB | 3 (1.9) | 2 (3.2) | 1 (1.0) | 0.154 |
| IIA | 58 (36.2) | 17 (27.0) | 41 (42.3) | |
| IIB | 92 (57.5) | 42 (66.7) | 50 (51.5) | |
| IV | 7 (4.4) | 2 (3.2) | 5 (5.2) | |
| Adjuvant therapy | ||||
| Yes | 93 (58.1) | 46 (69.7) | 47 (56.0) | 0.121 |
| Chemotherapy, only | 61 | 27 | 34 | |
| CCRT | 32 | 19 | 13 | |
| No | 57 (41.9) | 20 (30.3) | 37 (44.0) | |
| Gemcitabine adjuvant therapy | ||||
| Yes | 70 (43.8) | 26 (41.3) | 44 (45.4) | 0.729 |
| No | 90 (56.2) | 37 (58.7) | 53 (54.6) | |
| hENT1 (intensity) | ||||
| 0 | 5 (3.1) | 5 (7.9) | ||
| 1 | 9 (5.6) | 9 (14.3) | ||
| 2 | 10 (6.2) | 10 (15.9) | ||
| 3 | 39 (24.4) | 39 (61.9) | ||
| 4 | 97 (60.6) | 97 (100.0) | ||
| DCK (intensity) | ||||
| 0 | 48 (30.6) | 33 (53.2) | 15 (15.8) | <0.001 |
| 1 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| 2 | 39 (24.8) | 19 (30.6) | 20 (21.1) | |
| 3 | 64 (40.8) | 10 (16.1) | 54 (56.8) | |
| 4 | 6 (3.8) | 0 (0.0) | 6 (6.3) | |
| RRM1 (intensity) | ||||
| 0 | 25 (16.1) | 21 (33.3) | 4 (4.3) | <0.001 |
| 1 | 15 (9.7) | 7 (11.1) | 8 (8.7) | |
| 2 | 66 (42.6) | 25 (39.7) | 41 (44.6) | |
| 3 | 43 (27.7) | 8 (12.7) | 35 (38.0) | |
| 4 | 6 (3.9) | 2 (3.2) | 4 (4.3) | |
| RRM2 (intensity) | ||||
| 0 | 16 (10.3) | 8 (12.7) | 8 (8.7) | 0.150 |
| 1 | 0 (0.0) | 0 (0.0) | 0 (0.0) | |
| 2 | 7 (4.5) | 1 (1.6) | 6 (6.5) | |
| 3 | 62 (40.0) | 30 (47.6) | 32 (34.8) | |
| 4 | 70 (45.2) | 24 (38.1) | 46 (50.0) | |
| hENT1 high+gemcitabine | 44 (27.5) | 0 (0.0) | 44 (45.4) | <0.001 |
| Others | 116 (72.5) | 63 (100.0) | 53 (54.6) | |
hENT1, human equilibrative nucleoside transporter 1; dCK, deoxycytidine kinase; RRM1, ribonucleotide reductase regulatory subunit M1; RRM2, ribonucleotide reductase regulatory subunit M2; AJCC, American Joint Committee on Cancer